Keep an eye on Intellia Therapeutics (NTLA).
Tomorrow, the company will present interim clinical data from its ongoing first-in-human studies of NTLA-2002 and NTLA-2001 for the treatment of hereditary angioedema (HAE).
According to the National Association for Rare Disorders, “Hereditary angioedema is a rare inherited disorder characterized by recurrent episodes of the accumulation of fluids outside of the blood vessels, blocking the normal flow of blood or lymphatic fluid and causing rapid swelling of tissues in the hands, feet, limbs, face, intestinal tract, or airway.”
With NTLA-2002, “The presentation will focus on the initial safety, kallikrein protein reduction and HAE attack rate data from the dose-escalation portion of the study. NTLA-2002 is Intellia’s wholly owned, second systemically administered in vivo CRISPR candidate,” according to a release. With NTLA-2001, “The study update will focus on the dose-escalation portion of the cardiomyopathy arm of the study.”
Ahead of the presentation, the NTLA stock is up $4 on a volume spike to 1.34 million shares.
If the stock can break above prior resistance around $70.31, we’d like to see it run back to $80.
